Category: Latest News
-
Artelo Biosciences moves into glaucoma research with fully funded clinical study
Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study evaluating its drug candidate ART27.13 for the treatment of glaucoma. The San Diego–based clinical-stage biotech company said the investigator-sponsored trial will be fully funded through support from Glaucoma UK and the Health and Social Care (HSC) Research & Development Division,…
-
Ovid Therapeutics secures $60M funding to advance epilepsy drug programs
Ovid Therapeutics Inc. (NASDAQ:OVID) said Wednesday it has raised $60 million through a private placement to support the continued development of its epilepsy drug candidate OV329, including expanding research into seizures linked to tuberous sclerosis complex and infantile spasms. The biotechnology company, currently valued at about $262 million, has seen its shares climb roughly 337%…
-
Gran Tierra Energy shares slide after multiple board resignations
Shares of Gran Tierra Energy Inc. (AMEX:GTE) dropped about 10% on Wednesday after the company disclosed that four members of its board had stepped down following disagreements tied to an audit committee investigation. According to a regulatory filing, Evan Hazell, Sondra Scott, David Smith and Brad Virbitsky resigned from the board on March 11 and…
-
Jabil tops Q2 estimates and lifts full-year forecast on strong data center demand
Shares of Jabil Inc. (NYSE:JBL) rose about 1% in premarket trading on Wednesday after the electronics manufacturing services provider reported second-quarter results that exceeded analyst expectations and increased its outlook for the full fiscal year. For the second quarter of fiscal 2026, the company posted adjusted earnings of $2.69 per share, beating the consensus estimate…
-
Kanzhun shares decline after Q4 results announcement
Shares of Kanzhun (NASDAQ:BZ) fell about 4.4% after the company released its fourth-quarter financial results. The online recruitment platform reported adjusted earnings of $0.27 per ADS for the quarter, while revenue reached $297.2 million, marking a 14.0% increase from $260.8 million in the same period last year. The company said the performance was supported by…
-
Incannex says it holds $75 million in cash with zero debt after financing
Incannex Healthcare Inc. (NASDAQ:IXHL) said it currently holds about $75 million in cash and carries no debt following the completion of a recent financing round backed by healthcare-focused institutional investors, according to a company statement. At current trading levels, the clinical-stage biopharmaceutical company has a market capitalization of roughly $46 million, implying what the company…
-
CF Industries shares drop after Mizuho downgrades stock
Shares of CF Industries Holdings (NYSE:CF) fell about 3% on Wednesday morning after Mizuho lowered its rating on the fertilizer producer, warning that the stock’s recent rally may have gone too far. Mizuho analyst Edlain Rodriguez downgraded the shares to Underperform from Neutral and set a price target of $100, well below Tuesday’s closing price…
-
General Mills misses Q3 earnings expectations as sales decline
General Mills Inc. (NYSE:GIS) reported third-quarter results that came in below Wall Street forecasts, as adjusted earnings fell short of expectations and net sales declined from a year earlier. The food manufacturer posted adjusted earnings of $0.64 per share for the quarter, missing the analyst consensus estimate of $0.73 by $0.09. Revenue totaled $4.4 billion,…
-
Rocket Lab shares dip after announcing $1 billion equity offering plan
Rocket Lab Corporation (NASDAQ:RKLB) shares declined about 3.5% on Wednesday morning after the company revealed plans for a $1 billion equity distribution program. In a filing with the U.S. Securities and Exchange Commission dated March 17, 2026, the space technology firm said it had signed an equity distribution agreement with a group of financial institutions,…
-
SailPoint shares slide after weak outlook overshadows in-line Q4 results
Shares of SailPoint (NASDAQ:SAIL) dropped sharply in premarket trading after the identity security company reported fourth-quarter results that largely matched expectations but issued a weaker-than-anticipated forecast for the current quarter. The stock fell around 11% ahead of the opening bell. SailPoint reported fourth-quarter revenue of $295 million, representing a 23% increase year over year and…